Actinium Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. (ATNM) on December 9, 2022, regarding an event occurring on December 8, 2022. The filing addresses the adjournment of the Company's 2022 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
The primary material event is the adjournment of the 2022 Annual Meeting of Stockholders. Originally scheduled for December 8, 2022, the meeting was postponed to allow additional time for stockholders to vote. The meeting is rescheduled to reconvene on December 30, 2022, at 9:30 a.m. Eastern Time at The Garden City Hotel in Garden City, NY.
Outlook, Risks, and Management Commentary
- Proxy Solicitation: The Company will continue to solicit proxies during the adjournment period.
- Voting Status: Proxies previously submitted will be voted at the reconvened meeting unless properly revoked.
- Voting Deadline: Stockholders who have not yet voted must do so by December 29, 2022, at 11:59 p.m. Eastern Time.
- Voting Methods: Voting is available via the Internet (www.AALvote.com/atnm), telephone (1-866-804-9616), or mail.
- Assistance: Stockholders may contact Alliance Advisors, LLC for assistance at 1-877-777-2857.
Key Facts for Investor Verification
- Verify the reconvened meeting date of December 30, 2022.
- Confirm the voting deadline of December 29, 2022, at 11:59 p.m. ET.
- Check if previously submitted proxies remain valid for the new meeting date.
- Review the proxy statement for the specific proposals to be voted upon.